Procter & Gamble: UBS Maintains Buy Rating, Lowers PT to $180.

Procter & Gamble: UBS Maintains Buy Rating, Lowers PT to $180.

In a recent move, UBS analyst Peter Grom has revised the price target for Procter & Gamble (PG) from $186 to $180, while maintaining a Buy rating on the company's shares [1]. This adjustment comes amidst a backdrop of mixed analyst sentiment and ongoing market pressures.

According to data from GuruFocus, the estimated GF Value for Procter & Gamble in one year is $166.48, suggesting an upside of 8.29% from the current price of $153.73 [2]. The GF Value is calculated based on historical multiples and future performance estimates.

The average price target from 23 analysts is $173.44, with a high estimate of $186.00 and a low estimate of $144.22 [1]. This implies an average upside of 12.82% from the current price. The consensus recommendation from 27 brokerage firms is 2.2, indicating an "Outperform" status [1].

Procter & Gamble's recent stock performance has been impacted by a downgrade from Evercore ISI to an "In Line" rating from "Outperform" due to the growing challenge from Amazon [3]. The firm expects Procter & Gamble's FQ4 earnings report to be impacted by Amazon's market share growth, which now accounts for 50% of all HPC growth in the U.S. [3].

The upcoming FQ4 earnings report on July 29 will provide more insights into Procter & Gamble's ability to navigate these challenges. The stock has shed 6% this year, reflecting investor concerns about the company's ability to maintain growth in the face of increasing competition from online retailers [3].

References:
[1] https://www.gurufocus.com/news/2984161/ubs-adjusts-price-target-for-procter-gamble-pg-to-180-pg-stock-news
[2] https://www.ainvest.com/news/procter-gamble-downgraded-evercore-isi-q4-earnings-report-2507/
[3] https://finviz.com/quote.ashx?t=PG